Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KD6005 in Healthy Participants and Participants With Rheumatoid Arthritis
NCT06213259Phase 1Completed
- Sponsor
- Shanghai Kanda Biotechnology
- Start
- Jan 2024
- Primary completion
- Jan 2025
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of KD6005 in rheumatoid arthritis (RA) (4 arms), sponsored by Shanghai Kanda Biotechnology. Primary endpoints: Incidence and safety profile of participants with adverse events and serious adverse events at 57 days, Percentage of Participants With Laboratory Abnormalities at 57 days and 6 more. Started Jan 2024; status: completed.
02
Drugs
KD6005
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06213259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06213259.